Q2
BVS — Q2 2026 Financial Report Analysis
Bioventus grew Q2 sales 3.8% to $153.2M on an 11.5% jump in Durolane-led Pain Treatments; GAAP EPS of $0.47 is inflated by a $24.6M tax gain, adjusted EPS rose only to $0.22, and the board has opened a sale review.